Cargando…
Plasma proteomics reveals an improved cardio-metabolic profile in patients with type 2 diabetes post-liraglutide treatment
BACKGROUND: Diabetes mellitus is a chronic multisystem disease with a high global prevalence, including in Saudi Arabia. The Glucagon-like Peptide (GLP-1) receptor agonist liraglutide is known to lower glucose levels, reduce weight and improve cardiovascular outcome. However, mechanisms underlying t...
Autores principales: | Ekhzaimy, Aishah A, Masood, Afshan, Benabdelkamel, Hicham, Elhassan, Tasnem, Musambil, Mohthash, Alfadda, Assim A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152203/ https://www.ncbi.nlm.nih.gov/pubmed/35616478 http://dx.doi.org/10.1177/14791641221094322 |
Ejemplares similares
-
Exploring Cardio-Metabolic Effects of Liraglutide in Patients With Type 2 Diabetes Through a Proteomic Approach
por: Ekhzaimy, Aishah Ali, et al.
Publicado: (2021) -
Urinary Proteome Differences in Patients with Type 2 Diabetes Pre and Post Liraglutide Treatment
por: Rafiullah, Mohamed, et al.
Publicado: (2023) -
Plasma-Based Proteomics Profiling of Patients with Hyperthyroidism after Antithyroid Treatment
por: Masood, Afshan, et al.
Publicado: (2020) -
Proteomic profiling of thyroid tissue in patients with obesity and benign diffuse goiter
por: Benabdelkamel, Hicham, et al.
Publicado: (2022) -
Proteomics Profiling of the Urine of Patients with Hyperthyroidism after Anti-Thyroid Treatment
por: Benabdelkamel, Hicham, et al.
Publicado: (2021)